Lymphocyte immunotherapy can improve pregnancy outcome following in vitro fertilization (IVF)-embryo transfer (ET) in patients failing to successfully conceive after two previous ETs

Check, Jerome H.; Liss, J.R.; Check, M. L.; DiAntonio, Ann; Duroseau, M

doi:10.1016/s0015-0282(03)00100-6

Cited by 5 publications

(9 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The effect of LIT in increasing the chance of achieving pregnancy was similar to that of Check et al. who reported improved pregnancy rates in IVF‐failure patients receiving LIT with their next cycle (38.3%, 70.3% and 90% with LIT versus 28.7%, 45.9% and 60% for untreated controls in three different reports) 27–29 but a significant increase had not been seen in RSA patients in the RMITG study 1 where pregnancy rates were only slightly greater (78%) in the LIT‐treated patients compared to the controls (75%). However, autoimmune testing in this study was quite limited, and infertility (requiring IVF) was not the major problem in these patients.…”

Section: Discussionsupporting

confidence: 75%

“…However, similar immune abnormalities are reported in women with classical recurrent miscarriages and losses prior to 6 weeks including ‘implantation failure’ (which can be detected as chemical pregnancies or late ‘heavy’ menses), 18–26 and Check et al. reported an improved pregnancy rate and live birth rate in IVF failure patients who were given LIT 27–29 . There has been some data on properties of the treatment maneuver, including dose–response and duration of protection, 15,24,25 but no information with respect to the dose of CD200 + cells and outcome has been generated.…”

Section: Introductionmentioning

confidence: 91%

See 1 more Smart Citation

ORIGINAL ARTICLE: Cell‐Surface CD200 May Predict Efficacy of Paternal Mononuclear Leukocyte Immunotherapy in Treatment of Human Recurrent Pregnancy Loss

Clark

2008

American J Rep Immunol

View full text Add to dashboard Cite

The number of CD200(+) paternal mononuclear leukocytes may be an important determinant of subsequent reproductive outcome in a subset of patients. A lower % CD200(+) cell number may also reflect hitherto unappreciated paternal factors bearing on reproductive success. It is feasible to recruit women to enter observational studies and to obtain useful data as a foundation for further studies. More complete patient characterization in a larger study is needed.

show abstract

Section: Discussionsupporting

confidence: 75%

Section: Introductionmentioning

confidence: 91%

ORIGINAL ARTICLE: Cell‐Surface CD200 May Predict Efficacy of Paternal Mononuclear Leukocyte Immunotherapy in Treatment of Human Recurrent Pregnancy Loss

Clark

2008

American J Rep Immunol

View full text Add to dashboard Cite

show abstract

“…An increase in pregnancy rate was not seen in the RMITG study, but was reported by Check et al. in an infertile population 168,238 . One patient miscarried a normal‐karyotype embryo; CD200 + cell dose was not low.…”

Section: Do Any Clinical Therapies For Pregnancy Failure Actually Work?mentioning

confidence: 64%

“…An alternative approach to an RCT is to ask if LIT rescues all normal karyotype embryos 232 . Fetal tissue must be obtained soon after onset of the loss and modern molecular analytical techniques must be used in addition to standard culture and karyotype methods for abnormal karyotypes 13,230–241 . One also needs a surrogate marker for the effect of LIT in the recipient.…”

Section: Do Any Clinical Therapies For Pregnancy Failure Actually Work?mentioning

confidence: 99%

REVIEW ARTICLE: Immunological Factors in Pregnancy Wastage: Fact or Fiction

Clark

2008

American J Rep Immunol

View full text Add to dashboard Cite

Whether maternal immune effector mechanisms with the exception of anti-phospholipid antibodies cause pregnancy loss, and whether effective treatment is possible are subjects of controversy. Hence, in this study the current literature was searched and critically reviewed. In both animals and humans, similar immune effector mechanisms are linked to pregnancy failure. Several levels of evidence indicate that treatments such as aspirin + heparin, intravenous immunoglobulins, corticosteroids, and transfer of allogeneic blood cells bearing paternal antigens may improve the live birth rate. Combination therapy appears promising, but better diagnosis of subgroups responsive to specific therapies is critical. There are fallacies and flaws in the logic of previous arguments against immunological mechanisms and therapeutic interventions. In order to select patients most likely to benefit from known treatments, more extensive immunological testing is required. It is also important to determine the karyotype of all failing embryos.

show abstract

“…Anti‐tumor necrosis factor alpha (TNFα) therapy was administered in patients with an TNFα:interleukin (IL)‐10 ratio >30.6 and/or IFN‐γ (interferon‐gamma):IL‐10 ratio >20.5 In these patients, two injections of Humira 40 mg subcutaneously were given 2 weeks apart generally initiated 30–120 days before starting a cycle of conception and discontinued prior to the onset of cycle stimulation. Some patients were self‐referred to a non‐Canadian clinic for lymphocyte immunization therapy (LIT) . In these cases, LIT was administered within 6 months preconception.…”

Section: Methodsmentioning

confidence: 99%